Colorectal Cancer (CRC) Recruiting Phase 1 Trials for Paclitaxel (DB01229)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Recruiting	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT07020221	A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors	Treatment	Carboplatin (DB00958) Cetuximab (DB00002) Gemcitabine (DB00441) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642) VS-7375 (DB22888)
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Treatment	Aflibercept (DB08885) Bevacizumab (DB00112) Carboplatin (DB00958) Fluorouracil (DB00544) Ipilimumab (DB06186) Irinotecan (DB00762) Leucovorin (DB00650) NEO-212 (DB17100) Nivolumab (DB09035) Paclitaxel (DB01229) Pembrolizumab (DB09037) Regorafenib (DB08896)
NCT05786924	Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies	Treatment	BDTX-4933 (DB24611) Cetuximab (DB00002) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Panitumumab (DB01269)
NCT04999761	AB122 Platform Study	Treatment	Bevacizumab (DB00112) Carboplatin (DB00958) Cisplatin (DB00515) Domvanalimab (DB18848) Fluorouracil (DB00544) Futibatinib (DB15149) Gemcitabine (DB00441) Paclitaxel (DB01229) Pamufetinib (DB20752) Pimitespib (DB14876) Ramucirumab (DB05578) Zimberelimab (DB17505)
NCT06917079	BBO-11818 in Adult Subjects With KRAS Mutant Cancer	Treatment	BBO-10203 (DB23219) BBO-11818 (DB23520) Cetuximab (DB00002) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Leucovorin (DB00650) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642) Platinum (DB12257)
NCT05824975	A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)	Treatment	Bevacizumab (DB00112) Doxorubicin (DB00997) Eribulin (DB08871) GI-102 (DB27141) Paclitaxel (DB01229) Pembrolizumab (DB09037) Trastuzumab deruxtecan (DB14962)
NCT06835569	A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations	Treatment	ALTA3263 (DB23814) Carboplatin (DB00958) Cetuximab (DB00002) Cisplatin (DB00515) Fluorouracil (DB00544) Gemcitabine (DB00441) Irinotecan (DB00762) Leucovorin (DB00650) Midazolam (DB00683) Oxaliplatin (DB00526) Paclitaxel (DB01229) Pembrolizumab (DB09037) Pemetrexed (DB00642)
NCT07223047	A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies	Treatment	BMS-986523 (DB30387) Cetuximab (DB00002) Gemcitabine (DB00441) Paclitaxel (DB01229) Pembrolizumab (DB09037)
NCT07259590	A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation	Treatment	Albumin human (DB00062) Cetuximab (DB00002) GFH375 (DB24007) Gemcitabine (DB00441) Paclitaxel (DB01229)